RNS Number : 5461G Renalytix AI PLC 26 November 2020 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing
RNS Number : 5327G Renalytix AI PLC 25 November 2020 Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes. Following the first price monitoring extension
RNS Number : 5304G Renalytix AI PLC 25 November 2020 Price Monitoring Extension The auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the prices and sizes of orders
NEW YORK, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported
RNS Number : 3896G Renalytix AI PLC 25 November 2020 Renalytix AI plc ("RenalytixAI" or the "Company") RenalytixAI Reports Financial Results for First Quarter of Fiscal Year 2021 NEW YORK , November 25, 2020 - Renalytix AI plc (LSE : RENX) (NASDAQ: RNLX), an artificial
NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today announced the
RNS Number : 1993F Renalytix AI PLC 13 November 2020 Renalytix AI plc (" RenalytixAI " or the " Company ") RenalytixAI to Participate in the Stifel 2020 Healthcare Conference NEW YORK , November 13, 2020 - Renalytix AI plc (LSE : RENX) (NASDAQ: RNLX), an artificial intelligence-enabled
NEW YORK, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces the
RNS Number : 4449E Renalytix AI PLC 06 November 2020 Renalytix AI plc (" RenalytixAI " or the " Company ") Change of adviser NEW YORK , November 6, 2020 - Renalytix AI plc (LSE : RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on
NEW YORK, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, confirms that the
